Cipla Receives USFDA Inspection Closure for InvaGen Facility; Shares Slip Over 1% 

Mumbai, August 4: Cipla Ltd. said the US Food and Drug Administration (USFDA) has completed its inspection of the manufacturing facility operated by its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., in Hauppauge, Long Island, New York. 

According to the company’s exchange filing, InvaGen has received the Establishment Inspection Report (EIR) from the USFDA, officially marking the closure of the inspection. 

The inspection was a Pre-Approval Inspection (PAI) that the regulator had conducted at the facility earlier this year. Cipla had first informed exchanges about the inspection on February 10, 2026. With the issuance of the EIR, the regulatory process for that inspection has now concluded. 

An EIR is generally issued after the USFDA completes an inspection and finalises its review. Receiving the report indicates that the inspection has been closed, an important regulatory milestone for pharmaceutical manufacturers supplying products to the US market. 

The company did not disclose any financial impact or provide additional details regarding products linked to the inspection. 

Stock Market Snapshot 

The announcement had little immediate impact on investor sentiment. 

As of 9:21 AM IST on August 4, 2026, Cipla share price was trading at ₹1,458.30, down ₹16.10, or 1.09%, on the NSE. 

The decline suggests the regulatory update was largely viewed as routine by the market, with broader market sentiment and stock-specific factors likely influencing trading during the session. 

Company Background 

Cipla is one of India’s largest pharmaceutical companies, with a diversified portfolio spanning respiratory, anti-infective, oncology, cardiovascular and chronic care therapies. The company has a significant presence in regulated markets, including the United States, where compliance with USFDA manufacturing standards is critical for product approvals and commercial supply. 

Its subsidiary, InvaGen Pharmaceuticals, serves as one of Cipla’s key manufacturing and development platforms for the US market. 

Conclusion 

The receipt of the Establishment Inspection Report removes an important regulatory overhang for InvaGen’s New York facility and formally concludes the USFDA’s inspection process. 

While the update does not have an immediate financial implication, successful closure of regulatory inspections remains a key aspect of pharmaceutical manufacturing, particularly for companies with a meaningful presence in the US generics market. Investors will continue to monitor future product approvals and regulatory developments at Cipla’s manufacturing facilities.  

Source: 

• https://www.nseindia.com/get-quote/equity/CIPLA/Cipla-Limited 
• https://nsearchives.nseindia.com/corporate/CIPLA_04082026085728_SE_Intimation-US_FDA_EIR04082026.pdf